Brusatol enhances the chemotherapy efficacy of Cisplatin and Gemcitabine in KKU-100 cholangiocarcinoma cells through ROS-mediated apoptosis
Tueanjai Khunluck, Ingon Inson, Chartinun Chutoe, Laddawan Senggunprai, Auemduan Prawan, Kornkamon Lertsuwan · 2026
Read Brusatol enhances the chemotherapy efficacy of Cisplatin and Gemcitabine in KKU-100 cholangiocarcinoma cells through ROS-mediated apoptosis by Tueanjai Khunluck, Ingon Inson, Chartinun Chutoe, Laddawan Senggunprai, Auemduan Prawan, Kornkamon Lertsuwan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13578759.txt.
Description
Tueanjai Khunluck and colleagues pair a plant compound called brusatol with standard chemo drugs against bile duct cancer cells, in a 2026 lab study. This cancer resists the usual drug pair, cisplatin plus gemcitabine, so new helpers are prized. Cells of one human line were dosed with the compound alone and in mixes, then checked for survival, stress chemistry, and death signals.
Mixes pushed reactive oxygen inside the cells higher than the drugs alone. Death switch enzymes woke on both known routes, cell powerhouses lost their charge, and far more cells died the programmed way. Colonies shrank, and cell crawling and invasion both fell. The authors cast brusatol as a promising partner drug, with animal and safety work still ahead before any patient use.
Catalog record
| CREATOR | Tueanjai Khunluck, Ingon Inson, Chartinun Chutoe, Laddawan Senggunprai, Auemduan Prawan, Kornkamon Lertsuwan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53784 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |